35 Burst results for "Alzheimer's Disease"
The Bio Report
"alzheimer disease" Discussed on The Bio Report
"Can we measure the effects of that? And so all of that, I think, is something we're actively researching right now. In the case of these conditions, developing what's called a lark two inhibitor, this is for Alzheimer's disease and a separate one for Parkinson's disease. These are both in preclinical development, but can you explain what lark two is and how it interacts with the NLRP three inflammasome? Sure, yeah. So R two is a member of a family of proteins called kinases. And these kinases are enzymes that regulate the activity of other proteins. So they will activate or inactivate different proteins inside the cell. So we've known about for a few years that if you have a genetic polymorphism or mutation, you could call it, you have a different DNA sequence that encodes a different flavor of the lark two protein, you actually have a higher risk for developing neurodegenerative diseases like Parkinson's disease. And that's been studied pretty extensively. We actually discovered that a protein that lark two is involved with plays a very important role in protection from Alzheimer's disease. And so we got interested in Alzheimer's disease. And what we discovered is that this protein that lark two regulates plays a really important role in activating the NLRP three inflammasome. And the way that it does it is the protein that lark two regulates an Alzheimer's is called rab pen, RAB ten, and rab ten is kind of a traffic comp inside the cell. It tells proteins where to go. It sends some proteins to the membrane. It sends some proteins to other places inside the cell, and as I mentioned earlier, the inflammasome is very sensitive to getting the right proteins in the right place at the right time. And so wrapped in is really really critical. The function of rap ten is really critical to organize these protein complexes. And so what we've discovered is that people that have mutations in rab ten have less incidence of Alzheimer's disease. So we thought, well, if we can target lark two, we could diminish the activity of rab ten to a level where we could actually see protection from neurodegeneration. And so that's what our focus is. And we've been able to show that our compound can actually reduce neuroinflammation downstream. Sorry, upstream of NLRP three by changing this regulation of where these proteins are going inside the cell. And as the expectation that this might halt progression could it slow progression or would it be even possible to reverse disease
The Bio Report
"alzheimer disease" Discussed on The Bio Report
"So the first stage is we just give one dose one single dose of the drug and then we give a very low dose and then we give them a little higher dose and a little higher dose. So that's called dose escalation and so we'll dose escalate and we'll get a sense of how much the drug gets absorbed and how it gets eliminated. And if there's any potential safety issues and then we do what's called a multiple sending dose where we give ten days in a row or 14 days in a row where every single day they take the drug and we do the same thing. We ask how is it absorbed, how it's eliminated and what potential safety signals. So we're wrapping those studies up right now. We should be done with both we were done with the first stage in the second stage we should be done in this just in the next couple months. And as soon as we finish, then we will roll into what's called a phase two clinical trial and usually in a phase two trial, we're taking real patients that have real diseases that we think are our drug will have a benefit in and we'll test that in those patients. So we currently have two different phase two trials that were designing right now. We work with the FDA and we work with clinical investigators to make sure that the clinical trial design is appropriate and doesn't put patients at risk, but allows us to figure out whether the drug actually does what we think it does. And so that's the exciting part is after you get through this first stage, the second stage is phase two trials. You're treating real real patients and you get an idea. Does this do what we think it does. So all the work that we've done, you know, really kind of points to this next phase. And so we're excited to get those underway.
The Bio Report
"alzheimer disease" Discussed on The Bio Report
"So we basically, it's like a lock and a key and the next 7 is the key and we change the shape of the key so it doesn't fit in the lock anymore. And so that prevents the formation of the inflammasome complex. And in fact, our drug does something pretty pretty unique, which is we can actually disassemble the complex once it's once it's formed by pulling next 7 out of that protein complex. So it has a unique mechanism of action and we're excited to be the first ones to try a drug that works in this way. You're developing this for a range of conditions. Have you identified a lead indication? Yeah, it's something we talk about every day as you can imagine. One of the things that, you know, when you're developing a drug, you're certainly interested in the mechanism of how your drug works. I just explained to you our drug binds to next 7. And so part of how you choose what indication or what patient population you're going to test this drug in is you want to know that your target is intimately involved in the disease that you're trying to target. And in our case, it seems to be involved in every place that we've looked. And so that didn't help us narrow things down very much. And so the second thing that you normally try to do is to find out where does your drug like to go in the body? Because when you take an oral pill like this drug is, you know, the drug gets absorbed in the intestines and then goes into the liver and then goes into the bloodstream and goes all over the body. Well, every drug has kind of a different distribution pattern. So it doesn't go everywhere equally.
The Bio Report
"alzheimer disease" Discussed on The Bio Report
"And when it gets activated, the goal of this complex is to produce signals that tell the body there's a problem. And those signals will recruit different kinds of immune cells to come to the place where the signal is being released from. And that's really the role of the NLRP three inflammasome. So under normal conditions that inflammasome will form for a very short period of time, release those signals and then it goes away. Under chronic conditions under disease conditions, that inflammasome stays in the on position. So the switch is turned on and never gets turned off. And the consequence of that is we're just we're just starting to realize how many far reaching implications that has in almost every disease that you can think of. Everything from Alzheimer's in the brain to inflammation in your eye, your skin, your lungs, your liver, your kidney. Every disease that we know of that affects every organ system in our body, at least has some component of this chronic inflammation associated with it. Well, so going after that target, how broad a range of diseases would you expect to be able to treat? Well, it just in the past ten years since the discovery of these big protein complex, there's been literally thousands of publications scientific studies that have been done connecting NLRP three inflammasome with different diseases. So we've actually ourselves tested our drug that we've been making at developing it halia. We've tested it in models of neural information in the brain, which plays a role in Alzheimer's and Parkinson's and multiple sclerosis and Huntington's disease. We've tested it in inflammation in the lungs. We've tested information in the heart in the blood vessels in the liver, and it works in the colon. It works on every model that we've tried it. And so we think this is a universal mechanism for chronic inflammatory diseases. And so there's many, many different applications. And almost too many to actually wrap our heads around sometimes. One of the challenges in going after a target like that is the potential to have off target effects. How precise can you be in going after disease with this and how much risk is there of dampening an immune response that you want? Yeah, no, and that is the main challenge. And when you're dealing with something that's such a new discovery, you know, we've only really just known, even though we made the discovery this existed about ten years ago, just in the last 5 years or so we've really understood more about the biology of how this is regulated. And the main concern about turning off a fundamental mechanism like this is are you going to make people have a dampened immune response? Will they be susceptible to infections? And that's actually, it sounds like a pretty easy thing to figure out, but it's actually not. The human immune system is pretty different than a lot of the animals that we use in laboratory research to study, you know, we use a lot of mice and rats and in research and those animals, they're immune system is tuned a little bit differently than ours. And so it's actually quite challenging to predict what the long-term consequences of if you have a drug, let's say you took this drug every day. What would that do to your ability to mount a normal immune response to something like a bacterial infection?
The Bio Report
"alzheimer disease" Discussed on The Bio Report
"A complex of proteins that plays an essential role in regulating the innate immune system known as the NLRP three inflammasome is becoming a growing target of interest among drug developers to disrupt immune cell signaling. Halle Therapeutics is developing a pipeline of therapies that target the NLRP three inflammasome to address not only inflammatory disorders like psoriasis and colitis, but neurologic conditions such as Alzheimer's disease. We spoke to David bears, president and CEO of halya, about the NLRP three inflammasome.
The Charlie Kirk Show
What Dr. Daniel Amen Learned From Analyzing Thousands of Brain Scans
"Important lesson from 83,000 brain scans. What is that lesson, doctor? What is the most important lesson that you derived from now? I think it's what, 247,000 brain scans, right? I mean, it's much more than that now. Is you are not stuck with the brain you have. You can make it better. And I can prove it. And we've done thousands of before and after scans. I do a series on Instagram called scan my brain. And about 16 months ago, I scanned Major League Baseball player, Troy gloss, who's the 2002 World Series MVP. And despite a lot of terrible and for concussions, he was drinking too much. He had lots of dark thoughts, he was suicidal. And I did his third scan last week, and it looked dramatically better. And he's dramatically better, which not only impacts him at impact. So he saw a correlation, you see the healthier brain, you also see symptoms improve and it's proof that this is 99% of the profession is missing it. And it's a long-term play. So it's not just, oh, let me give you this medicine and you're less depressed. Let me get your brain healthy. So long term, you have a dramatically decreased risk. For Alzheimer's disease. And I turned 69 this year. And one statistic that just horrifies me is 80 is 50% of people 85 and older will be diagnosed with dementia, or Alzheimer's disease. And I'm not okay with that, right? It's more normal to be demented that not to be demented. So as I take someone in their 20s, 30s, 40s, 50s. The idea is not to just get them symptom free to get them to fall in love with their and keep that healthy for the rest of their lives.
The Doctor's Farmacy with Mark Hyman, M.D.
"alzheimer disease" Discussed on The Doctor's Farmacy with Mark Hyman, M.D.
"Or following injury. When I was in medical school, this is huge. When I was in medical school, we learned that the only neurons you were born with, that was it. And if they ever were damaged, they were going in any way. They weren't coming back. We now know the brain continues to make new neurons and connections well into adulthood. And this concept really offers hope to anyone facing stroke, traumatic brain injury, mood disorders, addiction, and neurodegenerative conditions. Another concept is this one about dynamism flexibility and adaptability. So even things we used to view as inflammation and stress, we thought of them as universally bad. Well, they're not. They're key processes important for survival. Just like amyloid has a role too. And the key is to be able if we take the example of inflammation, we want to be able to generate an inflammatory response when called upon. If we get an injury, we get an infection, that's part of how we recruit the cells to the site of that injury or infection, deal with the invader, and then start to lay the seeds to repair the injury and then turn the inflammation back off again. In fact, it's really interesting to think about how sophisticated our immune systems are, did you know that at the same time we initiate and then inflammatory response to something, our immune system is already planting the seeds for resolution at the exact same time. And here's a key clinical pearl omega three fatty acids that we get from fatty fish, for example, they contain molecules known as resolve and protectants that help the immune system plant the seeds to resolve inflammation when it occurs. So when we think about resilience, it's not a static process, and it's not about whether we have stress or inflammation, it's about the dynamism and the ability to bounce back. So in healthy situations where a way can we sleep, we exercise and we recover, we feast and we fast, we have stress and then we relax and we recover, we have inflammation, and then we resolve it. So our bodies do really well when we allow the recovery periods and the oscillations. Interestingly, not the same as true for use of calories. I mean, a very healthy metabolic system is able to utilize whatever fuel is available and sometimes it might be a higher fat meal, sometimes it might be a higher carbohydrate meal, and when our metabolic pathways are healthy and resilient, they can also toggle back and forth to what's available to us. So when we think about loss of resilience, it's when we're constantly missing the recovery period missing episodes of fasting, misting, relaxation, after periods of stress. That's one of the system becomes out of balance. And when we're talking about Alzheimer's disease, again, it's a really scary topic. So there's generate a lot of fear, a lot of uncertainty, but there is a lot that's under our control and that's where we want to focus our energies. What factors are in our control? So now let's talk about a little bit about genetics and lifestyle. I mentioned the APOE four gene. So APOE is one of at least 20 to 30 different genes that have been studied for their potential interaction with lifestyle to play a role with risk of Alzheimer's disease. The APOE is the best studied one, and it is has several key functions in the body. It's involved in cholesterol regulation and transport, repair of brain injury, and it plays a role with the immune response. There's three different sizes of this APOE that exist. There's APOE two, apo E three, and APOE four. So if you think about this, you're going to have two copies of the APOE gene, one from mom and one from dad. The most common combination is to have two E threes. That is about 50% of the population. And that's considered average in terms of risk of Alzheimer's disease. APOE twos might actually be protected. Those are fairly rare. If you have one copy of the a two, it's actually associated with a lower than average risk of Alzheimer's disease. One copy of the E four, keep in mind this is population predictions not individuals. You'll see about two to three times as many cases of late onset Alzheimer's disease, not early onset. Late onset Alzheimer's disease and people who have one copy of the E four gene, as opposed to people who don't have any copies of the E four gene. And as I mentioned at the very beginning, if you look at all the people for whom two of their copies are in E four, there's about ten to 12 times more higher prevalence of Alzheimer's disease in that group compared to people who have none. But again, not all double E force get Alzheimer's disease. I can not underscore that enough. Interestingly enough, one of the ways another way that E 4 may play a role with risk, it could have been an adaptive advantage because there's evidence that people who have one or two copies of the E four gene have a much more robust immune response to infections. And that may have been adaptive back in our gatherer hunter days where the main goal was to make it to reproductive age, so we could pass our genes on. So if we could fight off all the pathogens and bacteria and fungi and parasites that we were exposed to on a regular basis, that was one of our biggest threats to survive a lot outside of starvation. So it may have been an adaptive advantage that that robust immune response that can tip over into maladaptive chronic inflammation may no longer be adaptive as we get older. So it's just interesting thought and theory.
The Doctor's Farmacy with Mark Hyman, M.D.
"alzheimer disease" Discussed on The Doctor's Farmacy with Mark Hyman, M.D.
"If you're eating donuts all day, you can take all the fish oil or vitamin D you want. It's not gonna do anything to fix your risk of heart disease, right? So you have to look at everything together. I hope you enjoyed today's episode. One of the best ways you can support this podcast is by leaving us a rating and review below. Until next time, thanks for tuning in. Hey everybody, doctor Hyman, thanks for tuning in to the doctor's pharmacy. I hope you're loving this podcast. It's one of my favorite things to do. And introducing you all the experts that I know and I love and that I've learned so much from. And I want to tell you about something else I'm doing, which is called Marx picks. It's my weekly newsletter, and in it I share my favorite stuff from foods to supplements to gadgets, tools to enhance your health. It's all the cool stuff that I use and that my team uses to optimize and enhance our health. And I'd love you to sign up for the weekly newsletter I'll only say that you once a week on Fridays. Nothing else I promise and all you have to do is go to doctor Hyman dot com forward slash pics to sign up that's doctor Hyman dot com and sign up for the newsletter and I'll share with you my favorite stuff that I use to enhance my health and get healthier and better and live younger, longer. Just a reminder that this podcast is for educational purposes only. This podcast is not a substitute for professional care by a doctor or other qualified medical professional. This podcast is provided on the understanding that it does not constitute medical or other professional advice or services. If you're looking for help in your journey, seek out a qualified medical practitioner. If you're looking for a functional medicine practitioner, you can visit IFM dot org and search their find a practitioner database. It's important that you have someone in your corner who's trained who's a licensed healthcare practitioner and can help you make changes, especially when it comes to your health.
The Doctor's Farmacy with Mark Hyman, M.D.
"alzheimer disease" Discussed on The Doctor's Farmacy with Mark Hyman, M.D.
"What's happening with your mitochondria? What's happening with your detoxification process? All of these things are things that we can look at and measure and see where they're at, what's your nutrient status? I mean, just for example, if you are low in certain B vitamins like B 12 folate and B 6 and you have a high homocysteine of let's say 14, which is even in the conventional labs is considered quote normal. It should be like 6 to 8, but if it's 14 year risk of getting Alzheimer's is 50% higher. And that's just a multivitamin basically. So we have so many amazing tools and techniques to use now to one evaluate the dimensions through a cognitive and two create a science of brain health and optimization, which is really what we need to do. Now you said 2030 and 40s, but there's going to be a lot of people that are listening here that are 40 and above. Are they out of luck? We could be doing. So that there may not be a diagnosis yet, you know, knock on wood. But are there still, is there still hope for people in the 40 plus crowd? I hope so. Because I'm in that crowd. Actually, a number of years ago, when I was 40, I had a brain scan, and it was frigging scary drew. It showed really dramatic under functioning hypo hypo functioning of the brain. And when you see this hypo functioning, it has to do with various insults to the brain that can be reversed. And at the time I had mercury poisoning mol toxicity Lyme disease, all of these are reversible causes of cognitive function and decline. And so I worked really hard on myself to clear all these things to get healthy to get rid of my line to go to my mold, get rid of my mercury and many other things, get my microbiome healthy. And I repeated the scan about ten, 15 years later, and my brain had completely healed. It was really amazing. All the brain blood flow is back, my brain function centers were working and it was like, you can at any age. And I can tell you case after case and we can get into it a little bit later. I can tell you case after case of patients who have come to me with cognitive function, memory loss, early dimension, even more advanced dementia. And we see dramatic changes. So the brain is able to repair and heal at any age. And you always think, oh, you know, you have got so many brain cells and basically that's it. And if you drink too much and party too hard in college while you're kind of screwed. And you're never going to get it back. Well, not absolutely is not true. We know from actually autopsy studies, they've done, for example, on brain, on cancer patients, and they found that they gave them these radioactively labeled dyes that were only inactively replicating neurons. In other words, in new brain cells, you only see these being picked up that they were making new brain cells. And they literally were dying of cancer and they were still making new brain cells, which you could detect on imaging. That's really remarkable. And we know there's the whole field of neuroplasticity and neurogenesis. I mean, we can make new brain cells. We can actually increase the connections in the brain. You know, I'm learning tennis. I'm like, and I'm 15 years or so into it. And I'm keep improving and improving and working on it. And my tennis coach was like, yeah, this is really good for your brain. And learn new connections. In fact, tennis players will have an average of 7 years longer. And part of that is you're constantly working on different aspects of motor coordination, visual. It's a thing, right? So you absolutely can modify this risk at any age. Just for clarification for the audience, what was the brain scan that you did? What was the type of brain scan that you did? And would you recommend it to individuals who are listening today if they're trying to get a sense of where their brain health might be? Yeah, so there are many types of brain scans. The typical brain scan for Alzheimer's is an MRI, which can look at both brain volume overall volume of the brain and shrinkage. It can look at hippocampal volume, which is the size of the memory center of the brain, which shrinks with dimension, actually can grow back when you apply some of these principles of functional medicine to brain health. And that's sort of the standard test and it can also look at amyloid. There's actually imaging that looks at amyloid plaque in the brain. So you can see various amounts of amyloid, which is the thing that actually seems to cause the gunging up in the brain. The question is, what is the amyloid? What's it doing? Should we be trying to deal with it? There's a whole deeper conversation we can have, but it's kind of a rabbit hole. But essentially, it's inflammation. And then there's even more advanced scans that can look at early inflammation in the brain. Now there's a sort of more advanced functional MRI scans that can look at inflammation. And those are really emerging. I honestly, if those were readily available and the cost was reasonable, which I think it will be eventually, right? All the we're seeing exponential technologies where the price goes down and the power goes up. And we're seeing that across the spectrum, including imaging.
The Doctor's Farmacy with Mark Hyman, M.D.
"alzheimer disease" Discussed on The Doctor's Farmacy with Mark Hyman, M.D.
"I know where you're coming from. But listen, if we can show that we can improve symptoms and amyloid goes down in the blood, well, then we've just reversed Alzheimer's. I will be the first person to plant the flag in the ground and say, we have just reversed Alzheimer's. It would be the first person to do it. And there are studies that show that hippocampal volumes go up that you can improve the neurocognitive testing that you see all those hardcore biomarker changes, there's not enough of that data, but there's some of that data out there. Oh, I mean, you're preaching to the converted here. I mean, I have this amazing guy in Italy who, you know, the first MRI at baseline. Oh, and by the way, it's like, by the way, hippocampal volume, hippocampus is for those listening is the part of your brain that's the memory part that shrinks as you get older and shrinks a lot when you get dementia. And if it grows, it's not supposed to grow. Yeah, and so again, this is an anecdotal story, but there have been studies that have shown this also. I remember one of the first times I saw, I saw guys brain, a guy from Italy, nice guy. He came in this really fancy Italian studios while dressed. He was skinny fat though. He was skinny fat. He had elevated body fat, although you couldn't see it because of the fancy clothes. And you know, after a year and a half, he came back and we looked at his brain. You could see it through the eyes. You could see it through a computer automated software. The memory center in the brain after following a comprehensive plan through I think exercise is a big driver of volume, brain size, making the brain bigger. But I think it was everything. But you could see with your own eyes and untrained eye could see that the hippocampus got bigger a year and a half later. His cognitive function got better. Memory function was better. He was no longer skinny fat. He gained muscle mass and lost body fat around the waist size. The bigger the belly, the smaller the memory center in the brain. He got rid of the belly fat, the memory center in the brain got bigger. Now, this is an anecdotal study and some of the naysayers out there would say, oh, stop already, you're just given this N of one study. But no, there's actual research that shows this too that exercising increases hippocampal volume. So, you know, if I think the Holy Grail and the next big study that we do, and it's going to have to be multi site. And we were just starting to work on this before COVID and then COVID really, really messed things up and obviously for the world, but also for Alzheimer's disease research. Our goal is to do what we're trying to plan is more of a telehealth telemedicine study where doctors can take care of people at risk for Alzheimer's and we can do a lot through telemedicine so we can break down barriers, keep the cost below. But then get blood tests get amyloid at baseline, get amyloid a follow-up. Maybe get MRIs at baseline MRIs that follow up. And basically try to enroll people from all over the place rather than just one site because we were the main site that enrolled in New York. We're going to basically try to prove this time that not only are we improving symptoms. Are we slowing decline, but I would love to be able to shout off the mountain tops that we were able to reverse Alzheimer's disease and prevent it from a neuropathological perspective. And if we have those data, I really believe that, you know, the naysayers aren't going to have any tomatoes to throw. Because not only about the naysayers, it's about all the people suffering to have finally hope. I mean, people with cancer have hope. People heart disease have folks people with diabetes. People with Alzheimer's, it's like, oh, wow. It's like dropping a nuclear bomb on somebody. And it's kind of the worst diagnosis you can possibly get because you lose yourself.
The Doctor's Farmacy with Mark Hyman, M.D.
"alzheimer disease" Discussed on The Doctor's Farmacy with Mark Hyman, M.D.
"When I was an intern. Yeah, before the south beach diet before, you know, he's a healthy diet guy, but to me, he's the easy agates in calcium score guy, like this to me. He's the visionary that was one of the first preventative cardiologists. And preventing disease and starting before there are symptoms, it was so the tomatoes that were thrown at me were the big vine ripe tomatoes. They were big. Now, I don't know if my reflexes are better, I have cat like reflexes now to cap behind me. But I can Dodge the tomatoes better. My armor is thicker. The tomatoes are not being thrown as well. But it's also because, you know, we've now published, we publish results. And you know, I talked to a journal editor 5, 6 years ago, and I said, well, this, this and this and this, and this is what I see. And it's clear. And he said, well, it may be clear to you, but you need to prove it. And then you need your peers to review the article and accept that your thoughts and your observations are substantiated by evidence. And I feel like in the last 5 years, this 8 years, actually, we've been able to do about as good a job as possible with the limited resources that we have. Now, if that 1% of the billions of dollars or heck, 10% of the billions of dollars would have come in the prevention bucket, I can tell you if someone drops a very large sum of money in our research program to prove this, we can do it, but it's hard. Prevention studies are expensive because they take longer. Prevention studies need to follow people for years rather than 6 months or 9 months or a year. So I think the reason that my colleagues are coming around is because of the publications and building the body of evidence. I think the other reason that my colleagues are coming around is several of them have come visit. I don't have 45 other physicians and other healthcare providers come visit me and sit next to me and if someone isn't willing to sit next to me and if someone is willing to criticize the work we do, but not willing to come sit next to me and spend a couple hours and just watch. Just look. Oh, this is only one patient. And it doesn't mean anything. When you see this once and you get again and you see it at 9 o'clock 10 o'clock 11 and then 1 o'clock, 2 o'clock and three 30. Okay, fine. Prove it, I get that. But there are still skeptics out there. There are still skeptics that still get criticism every day. And I don't want to say jaded, but haters gonna hate. I'm going to keep doing my thing. And you know, you know, a Max Planck said, right? No. He said that? No, he said, science, but you could say medicine doesn't evolve by convincing your opponents and helping them see the light. Because they eventually die in a new generation grows up. That's familiar with it. In other words, medicine progresses one funeral at a time. That's kind of mean, but that's what he said. And I think the other point is that the absence of evidence isn't the evidence of absence. If we haven't spent billions of dollars studying nutrition in Alzheimer's, how the heck do we know anything? We spent billions of dollars studying drugs that don't work, but not the right things. And the other thing we should I'm going to push back pretty hard on this for you because you keep talking about preventive neurology and preventing Alzheimer's. And yes, yes, we should do all that. But your study, your own study showed that you can not only prevent it, but reverse the symptoms. Now, how far can we go to reverse it? How much can we reverse it? How far can these treatments work? What if we added ten other things that maybe we haven't even thought of that might be as or more impactful than the 25 things you're already doing? I would push back and start to encourage you to think about treatment studies, not reversal studies, because those you'll see outcomes much quicker. And if you can take a group of ten, 20, 50 people. And be really aggressive. And it's not easy because changing and I have these patients. I'm treating many of them right now. It's the roughest thing because if you have an engaged patient, you know, something that a heart attack and you tell them to change their diet and their vitamins and exercise and go, I get it. But you've got someone with dementia or cognitive impaired, they can't remember stuff. You need a full-time bodyguard, literally with them. Telling them what to do and helping them do it. But if you did those kinds of studies, I think you would see dramatic changes. So, you know, I'm really cautious and I would use the term hesitant and actually I would use the term. I don't use the term reverse. And the reason is, and let me explain my position here. Because, you know, I respect where you're coming from. And I see, I see why that term has been used in the past, but until I have definitive biomarker evidence that I am reversing the signs of pathology. Now, if I would have done my study and we had the blood test, the amyloid blood test out. Now it's out. Now it's out. So if 2015 and 2014, if we would have gotten the amyloid samples in the blood, and then 18 months later, we got them again. And if I would have shown not only did we improve symptoms, so you can either use the term symptomatic benefit, improve symptoms, you can use the term reverse symptoms. I don't like that term because I understand reverse to me implies neuropathological reversal and I want to be like, I'm trying to build bridges here and I'm trying to bring my enemies closer.
The Doctor's Farmacy with Mark Hyman, M.D.
"alzheimer disease" Discussed on The Doctor's Farmacy with Mark Hyman, M.D.
"Followed this plan, 18 months later, as long as they followed 60% or more of what I recommended had better cognitive outcomes, 18 months later. We were able to improve there's no drug that can improve symptoms at slowing decline is one thing improving symptoms. So I'm zen with not being able to precisely understand which of my 21 things are working. But I think as clinicians, I think we just have to do the best we can. And we want to promise not to over promise. I think that's important too. You said at the beginning when you were seeing that patient, I'm not a 100% sure, you know, yada, yada, but I'm going to try all the usual things. And you know something worked. So I think as long as we have honest conversations with our patients and do the best people like us that have academic appointments and are in that realm, I think it's my duty in some ways at this time in my life and my career to try to prove as much as I can, but I think the field and I think people need to realize that some things are really hard to study and prove. Yeah. And they are, but it's happening now is with the acceleration of our understanding of how to map biology and things we couldn't even measure before. We're able to start to look at different diagnostics than we ever did before. And find things we never found before. And within the Diaspora of medicine, which is where I've been most in my life. There has a lot of people doing really interesting diagnostics that are ignored, like heavy metal testing. For me, that's like a blood pressure when someone comes in and they have any kind of toxic or immune or cognitive or any chronic symptoms. I look at it because it's often an annoying factor was actually how I figured this all out was through my own mercury poisoning from living in China and I had severe cognitive impairment and also community dysregulation and gut issues. And I think the gut stuff is such a big deal. And that's how we can start to understand what the microbiome and its effect and there's data coming out. Then the question is, as clinicians, we never learn, well, how do we repair a microbiome that's off? How do we do that? Okay, well, we may know, okay, if you're low in vitamin D, take vitamin D, but if we test the microbiome and there's all this inflammation and dysbiosis and like the average Doc has no clue where to start. So I think that's part of the problem is we just don't have one, some of the diagnostics we need or if we do the average practitioner has no clue what to do with it. And I think we're all going to all that's going to change. I think what you're talking about is managing something that until now I don't think has been able to be managed by the average doctor, which is, God, there's a hundred things we could find that could affect the brain. I think there's probably a thousand, or maybe there's 10,000. But the average person and the average doctor can not process all that. And make the connections. But with the advent of quantified self metrics, which you talked about with the advent of advanced diagnostic metrics and metabolomics and the understanding of the microbiome metabolomics, for example, nobody talks about that, but the metabolism of the microbiome, and your blood, there's probably 20 to 50% of the metabolites in your blood come from the bugs in your gut. And how does all that work? Well, that's going to require big data and machine learning and artificial intelligence. And they start to see the data and the patterns and connections. So I think that's where this all headed and we have to stop this paradigm of being reductionist and saying, just take this one drug for Alzheimer's. And I get so frustrated when I hear these studies come out and they have big news articles and helps that helps. I'm like, what about all the rest of this stuff that Richard's talking about? It's got to be frustrating for you too because you see it. You see your patients get better and you go, hey guys, why don't you try this? And what are your Friends say who are also neurologists or memory specialists? Do they think you're a quack or are they like listening? You know, I'm a pretty resilient guy. I gave my first talk in 2007 about how MCI mild cognitive impairment due to Alzheimer's and this pre symptomatic. I didn't like that term. I just felt it should be prodromal at risk, you know, I felt like we should be treating people before they had dementia. And when I kind of set that stage and I wrote about this in one of my books, names not naming names, but I didn't name the name there too, but one of the Giants in the field was sitting there and like just, I don't say rolled their eyes, but just there's no evidence. There's no evidence here. There's nothing you can do. There's no evidence for die. There's no evidence for this. There's no evidence for that. But there was no impetus to even aim to study it. You know, I started seeing Alzheimer's prevention patients in 22,009. Doctor Arthur Agatha was one of my mentors. Oh, yeah, Arthur. Amazing guy. You know, he was my attending at Mount Sinai medical center when I was an intern. Yeah, before the south beach diet before, you know, he's a healthy diet guy, but to me, he's the easy agates in calcium score guy, like this to me. He's the visionary that was one of the first preventative cardiologists. And preventing disease and starting before there are symptoms, it was so
The Doctor's Farmacy with Mark Hyman, M.D.
"alzheimer disease" Discussed on The Doctor's Farmacy with Mark Hyman, M.D.
"Basically home, not able to do anything depressed, not functioning. It was the former sea of his company. He also he also had other nutritional efficiencies like vitamin D and he had been living in Pittsburgh and in Pittsburgh, it's the capital of steel. And for a century, they've been burning coal for the steel plants, and they use cold air for the streets on the winter for ice. They put it on the fields for fertilizing what they do. It's everywhere. And all my patients and Pittsburgh have high mercury levels. And he had very, very, very high mercury levels when we did a challenge test, he was on a mouth full of fillings. And we know that if you look at amalgam scores, the surface area and you look at animal studies, the more amalgams we put in their mouth, the more mercury ends up in their brain. And so I said, well, I don't know, I don't know if anything I'm going to do is going to work, but let's fix in some resistance. Let's fix also we had terrible gut issues. He had irritable bowel for 30 years, went on stelazine for his stomach, which is a psychotic antipsychotic drug to calm his stomach down. And I fixed his stomach. I cleaned up his diet, fixed the insulin resistance. I fixed the B vitamin thing. I got rid of the metals. And the guy came back to life. And it was really, really remarkable. And he was able to go back to work and function again and be part of his family and be part of his society in a way that I was just shocked. And so I think that there's a level of stuff that we're looking at. And then there's a whole bunch of stuff we're not looking at. So I'd love you to comment on that and what your thoughts are about. All that other stuff that's going on. Yeah, so and thanks for sharing the story because every story is instructive because this is the article that I described. Editorial I wrote for a medical journal, I'll just because you'll go, wow. This is interesting. So, you know, the thing that resonates me with the story is, when you have people with APOE four fours, those are just different eggs and E four 4s may be, for example, E four forest may be preferentially responsive to vitamin D, for example. So some studies show that vitamin D, maybe it's not really that preventative. Oh, some studies show maybe it is more preventative. Well, people with two copies of the E four variant, which is again not super common. Those people really need to have their vitamin D up. And that's just an example there. But people with the APOE four variant pesticides, DDT and DDE, the interaction between E four and pesticides increases Alzheimer's risk several fold if people don't have the APOE four variant. Maybe they're not as exposed or maybe they're not as increased risk to Alzheimer's. So when you look at a whole population, you don't tease out for E four positive versus negative. The studies may not show any correlation, but in practice, we see the correlation. And in other studies, you do see the correlation. So I think something I was at a conference in Canada. You have a lot of fans in Canada, by the way. Just after your name came up there. True. It's everywhere I care. Istanbul, the airport and some guy from the security comes running up to me. I thought I was going to get arrested for smuggling something smuggling in my Turkish delights back to America. And you're like, thunder I met. Can I take a picture with you? And oh my God, fine, okay. International. So I was at this, I was at this thing in Canada, and amazing people just smart people. And we were given presentations. And of course, I'm like, you know, the science guy. And I'm like, I'm a clinician. I'm like a regular doctor. I want to say Joe schmo, like you and me. But I was thrown into this clinical research thing. And again, I had resources, infrastructure, did work hard to learn, hired the right people. So yes, I've done research. And when you do research, you need to have objective measures to follow that you can track. I was at this group encounter getting Gary and Elizabeth, Elizabeth, a naturopathic doctor. And Gary is just really, really, really smart. And they were working together to present on a topic. And it's kind of like a bulb lightbulb came off of my head. And I said, you know, I'm so focused in the objective because I need to be because I'm a researcher. If I'm going to say something and think it, I need to then prove it because if I'm in an academic environment, I was at wild Cornell medicine for a new Presbyterian for almost 8, 9 years now I'm at Florida Atlantic university doing a really really exciting program in brain health and Alzheimer's prevention Parkinson's prevention dementia with Lewy body prevention. You get to do some really cool things. Maybe I'm missing the boat a little bit because if I'm just focusing on the objective that I need to track and prove, there's a lot of stuff under the surface that I can't really track improve because I don't have a biomarker to do that. So I guess what I'm trying to say is as I've, I know what I know and I don't know when I don't know, I'm consciously incompetent about things. And the story that you say is no, there are people that are unconsciously incompetent and those people drive me a little bit baddie, but I am on your team. I know what I don't know. Yeah, I know what I don't know. And I'm willing to have my eyes open. And the stories that you say, it's like, as a physician, you have to treat someone in a certain way to try to make them better. But we don't always have all the objective evidence. And the types of work that we do on patients, it's really hard to study. I have empathy for people in our boat who are trying to study the rigorous rigorously study because what's moving the needle. To me, I don't care what's moving the needle. People were criticizing one of my research paper. Oh, you recommended 21 things? What if 18 of them are helping in three of them are harming, you'll never know. And I said, okay. But look at the results. 18 months later, people with amyloid in their brain with mild cognitive impairment due to Alzheimer's disease that followed this plan, 18 months later, as long as they followed 60% or more of what I recommended had better cognitive outcomes, 18 months later. We were able to improve there's no drug that can improve symptoms at slowing decline is one thing improving symptoms. So I'm
The Doctor's Farmacy with Mark Hyman, M.D.
"alzheimer disease" Discussed on The Doctor's Farmacy with Mark Hyman, M.D.
"Brain from Alzheimer's and with doctor Dale bredesen on what to look at in your body to reduce your Alzheimer's risk. Let's jump in. Alzheimer's disease is a medical disease. Yeah, full stop. That's it. There's this thing called the skull and it's a hard thing that protects you when you fall. But it's just like it's like when you have medical conditions, you can affect your kidneys. When you have medical conditions that can affect your eyes, it can affect your heart. The same thing it can affect your brain. And I couldn't agree with you more. People can take different roads to Alzheimer's. And you have to figure out what word they're on and get them the heck off that road. Women, for example, are unfortunately many times in the fast lane to Alzheimer's. Women, two out of every three brains affected by Alzheimer's or women's brains. And 5, ten years ago, I would say I didn't know why, and now I think I can answer that question. And it's related to the perimenopause transitions related to specific life factors. It's related to women being maybe a little bit more at risk. If they have the apo E four variant. So the take home point here is if you understand a person's individual risk factors, whether it's biological sex, whether it's medical conditions, whether it's what's floating around in their blood, whether it's, what is their cognitive function at baseline, you have to figure these things out, and then you have to target that plan and personalize that plan. And I mean, Alzheimer's disease and brain health needs to be treated in a medical way, because if it's not, if you're just targeting amyloid, you're missing the boat, you know, amyloid is a marker. And I think hopefully one day we're going to have just like we treat diabetes with lifestyle interventions and exercise, as well as certain targeted drugs that honestly, some of them actually do tend to work pretty well. I'm not the biggest fan of insulin like that. That's maybe band aiding to me. That's probably too late. I mean, I'm not the best, whatever, but some of these new things that are pretty interesting. I won't get into specifics. But I hope that one day we treat Alzheimer's disease and cognitive decline, like any other chronic disease of aging, where we hit things with a multimodal evidence based and safe approach. That requires a medical intervention. So essentially what you're saying to paraphrase is that Alzheimer's is not a brain disease. Correct. It's a systemic disease that affects the brain. Yeah, I really believe that. And I have to be careful saying that, is this being recorded? Yes. And it's going to be broadcast to billions of people around the world. I was just trying to I was just gaining some from some fans in my field. And now it's all ten decade of work. You were at the forefront of a paradigm shift that's happening throughout medicine, which is the breakdown of the old concepts of disease from simply this reductionist organ based symptom based model to systems thinking and network medicine. And that's really all you're talking about. And you know, you've touched upon some of the most easily accessible and modifiable factors, which is what we eat, how we exercise, how we handle and manage stress, how we sleep. Those four pillars are huge. And then there's the fine tuning with managing metabolic risk factors or getting their nutrient levels up to a certain level. But there's a whole treasure trove of stuff that I think still haven't even dug into. It's like, it's like, I visited Ephesus in turkey. And it's the largest Roman city during the Roman Empire. It was incredible. And it was all buried under dirt and rubble and they excavated it. But there's still excavating it. A hundred years later, and it's just fascinating to see that there's so much we don't know. And I would say, in my experience, as a functional medicine doctor, I've seen things that have impact on the brain that aren't really included. Heavy metals do we even have a way of testing that is in commercial medicine fundamentals, not really. We just do a blood test and then we don't worry about it if it's okay. But there may be total body burden of toxins we don't look at. The microbiome is another huge factor that affects the brain and Alzheimer's. And mitochondrial function is something you talk about, but is often ignored. And we have latent infections that may be affecting the brain cause inflammation, whether it's herpes, too, maybe link, but there may be other things. I mean, Chris just after had Lyme disease and got diagnosed with dementia. There may be environmental factors like mold that have impact on inflammation. So we know that the brain with patients with dementia is inflamed. And then the causes of that inflammation can be multiple. And so part of the diagnostic dive that you're doing and I would just encourage you to think about this is that you're getting to all the stuff that we do know that's so clearly evidence based. But then there's a whole treasure trove of things to look at that we're kind of ignoring. And I'm just going to take like two seconds. I know it's your podcast, but you're talking, but I'm just going to just talk about this one patient because it was the first patient I had where I'm like came in the guy with Alzheimer's like, can you do anything? I'm like, I have no clue. I don't know, but I'm just going to apply the model of systems of biology and functional medicine. Let's see what we do. We found he was severely in some resistant. He had which is, you know, we talk about Alzheimer's type three diabetes in the brain. He had very high homocysteine levels and methylation problems. So his genetics were off around metabolizing B vitamins in the right way, which we know is a risk factor for Alzheimer's. He had the APOE four double four gene. So he's the 1%. He was 7 years old. Cognitively impaired diagnosed with Alzheimer's, basically home, not able to do anything depressed, not functioning. It was the former sea of his company. He also he also had other nutritional efficiencies like vitamin D and he had
The Charlie Kirk Show
America Is Suffering From Alzheimer's Disease
"Are at a crisis right now in America where if we do not do something bold and dramatic, we're going to have an entire generation that suffers from historical Alzheimer's. That's exactly where we are right now. Our nation is suffering from Alzheimer's. We don't know where we came from, who we are or where we're going. It's very sad. I'm not trying to trivialize Alzheimer's. Have you ever dealt with somebody in that condition that's exactly where we are as a country. We can't remember our history. Turning point academy will restore the memory of the greatest nation ever to exist in the history of the world.
AP News Radio
US approves Alzheimer's drug that modestly slows disease
"The Food and Drug Administration has approved a drug that modestly slows Alzheimer's disease. It's called la chembe, also known as lakena mab. It's designed specifically for those with mild or early stage Alzheimer's. Doctor Sam Gandhi at New York's Mount Sinai hospital says it focuses on amyloid material that builds up in the brain. There's a particular type of amyloid called the oligomer. That's especially toxic, especially poisonous. And looking at is targeted toward that particular most toxic species. The delay in cognitive decline brought about by the drug likely amounts to just several months. We don't know what rate they would have progressed. If they hadn't gotten them the medication. So it's in terms of whether the drug buys them 5 months or so. It's hard to know how people can relate to that. There can be side effects, like is a rare success in a field accustomed to failed experimental treatments for the incurable condition. Ed Donahue, Washington.
Nutrition Facts with Dr. Greger
"alzheimer disease" Discussed on Nutrition Facts with Dr. Greger
"Finally today, we look at reducing intake to ward off Alzheimer's. Each of us has about 6 billion miles of DNA. How does our body keep it from getting all tangled up? Their special proteins called histones, which act like spools with DNA as the thread. Enzymes called sirtuins wrap the DNA around the histone spools and in doing so silence whatever genes were in that stretch of DNA, hence their name sir twins, which stands for silencing information regulator. Although they were discovered only about a decade ago, the study of sirtuins has become one of the most promising areas of biomedicine since they appear to be involved in promoting healthy aging and longevity. Suppression of this key host defense is considered a central feature of Alzheimer's disease. Autopsies of Alzheimer's victims reveal that loss of certain enzyme activities closely associated with the accumulation of plaques and tangles in the brain that's characteristic of Alzheimer's disease. Search winds appear to activate pathways that steer the brain away from the formation of plaque and tangle proteins. Because a decrease in sertraline activity can clearly have deleterious effects on nerve health, they're trying to come up with drugs to increase her to an activity, but why not just prevent its suppression in the first place? Glycotoxins in food suppress sertraline activity. These so called advanced glycation end products are AGEs. Our modern diet includes excessive AGEs, which can be neurotoxic, high levels in the blood, may predict cognitive decline over time. If you measure the urine levels of glycotoxins flowing through the bodies of older adults, those with the highest levels went on to suffer the greatest cognitive decline over the subsequent 9 years. As we age, our brain literally shrinks. In our 60s and 70s, we lose an average of 5 cubic centimeters of total brain tissue volume every year. But some lose more than others. Brain atrophy may be reduced and very healthy individuals in a few people don't lose any brain at all. Normally we lose about 2% of brain volume every year, but that's just the average. Although the average brain loss for folks in their 70s and 80s was 2.1%. Some lost more, some lost less, and some men and women lost none at all over a period of four years. Researchers in Australia provided the first evidence linking AGEs with this kind of cerebral brain loss. So, limiting one's consumption of these compounds may end up having significant public health benefits. Because sertraline deficiency is both preventable and reversible by a dietary AGE reduction, a therapeutic strategy that includes eating less AGEs may offer new strategy to combat the epidemic of Alzheimer's. Some of these glycotoxins are produced internally, particularly in diabetics, but anyone can get them from smoking and eating, particularly foods high, in fat and protein. In a previous video, I listed the 15 foods most contaminated with glycotoxins. Mostly chicken, but also pork beef and fish, which may help explain why those that eat the most meat may have triple the risk of getting dementia compared to long time vegetarians. We would love it if you could share with us your stories about reinventing your health through evidence based nutrition, go to nutrition facts dot org slash testimonials. We may share it on our social media to help inspire others to see any graphs, charts, graphics, images, or studies mentioned here. Please go to the nutrition facts podcast landing page. There you'll find all the detailed information you need plus links to all the sources we cite for each of these topics. For a timely text on the pathogens that cause pandemics, you can order the ebook audiobook or hard copy of my last book how to survive a pandemic for recipes, check out my second to last book. How not to diet, cookbook? It's beautifully designed with more than a hundred recipes for delicious and nutritious meals. And all the proceeds I receive from the sales of all my books goes to charity. Nutrition facts dot org is a nonprofit science based public service where you can sign up for free daily updates on the latest in nutrition research via bite sized videos and articles. Everything on the website is free. There's no ads, no corporate sponsorship, it's strictly non commercial. I'm not selling anything. I just put it up as a public service as a labor of love as a tribute to my grandmother whose own life was saved with evidence based nutrition.
Nutrition Facts with Dr. Greger
"alzheimer disease" Discussed on Nutrition Facts with Dr. Greger
"I'm often asked what my opinion about a diet or disease is. Who cares what my or anyone else's opinion is? All we should care about is what the science says. What does the best available balance of evidence published in the peer reviewed medical literature have to say right now? Welcome to the nutrition facts podcast. I'm your host. Doctor Michael greger. I know so many people have been diagnosed with Alzheimer's disease, the most common cause of dementia. I bet you do too. In fact, more than 6 million people in the U.S. have it. So how do we avoid becoming one of those statistics? That's a main thrust of my forthcoming book, how not to age, but in the meanwhile, here's the discussion of some little known risk factors in this our 300th podcast episode. In our first story, we explored the effect of pesticides on Alzheimer's disease. Although there's a growing list of Alzheimer's disease susceptibility genes, even if you put them all together, they account for less than half of all Alzheimer's cases. The single most compelling piece of data on the potential control we have over the disease is in fact, if you have identical twins with the exact same genes, even if one gets Alzheimer's, the other usually does not. So we have to think about all the other contributing factors beyond just genetics. In my video on pesticides in cancer, I talked about this study. There's a list of chlorinated pesticides, including DDE, metabolite of DDT, that are classified by the EPA as probable human carcinogens. But in the study, blood levels of DDE and others were associated not with increased cancer mortality, but increased risk of other cause mortality. This led researchers to speculate it may be due to an associating increased risk of diabetes or dementia, I've talked previously about the diabetes link, what about dementia? Elevated serum pesticide levels in risk for Alzheimer's disease. A research team at Rutgers found significantly higher blood levels of DDE and Alzheimer's disease patients compared to controls, and autopsy studies show blood levels are a good proxy for brain levels. Those with the highest levels, what about four times the odds of being demented with Alzheimer's and in a Petri dish is DDE increases amyloid precursor protein levels in human brain cells providing a potential mechanism. Put all these studies together. There does indeed seem to be a link consistent with data showing about a doubling of risk for developing dementia among those acutely pesticide poison. Among U.S. elders, DDT and its breakdown product DDE are also associated with the increased risk of cognitive decline in general. DDT was extensively used in the United States from the 1940s through the 60s, at its peak, we were turning out a 180 million pounds a year, and it still in our bodies to this day contaminating the bloodstreams of more than 90% of Americans indeed, the pesticide link to quadrupling the odds of Alzheimer's were at the highest levels. It's still in our bodies because it's still in the food supply. In my last video on the topic, I noted that the levels of DDT DDE and other banned pesticides and pollutants were much lower in the breast milk from a vegetarian mother compared to breast milk over non vegetarian sister, and the largest difference was noted for DDE, which was four times lower in the vegetarian sister. These toxins build up the food chain, so it makes sense that the most contaminated foods are meat, fish, and dairy products, 5 to ten times higher levels in meat, eggs, fish and dairy than what we find in plant foods. And unfortunately, cooking doesn't destroy pollutants like DDE. In fact, it may make them even more concentrated. And this is for a pesticide that may increase the risk of Alzheimer's disease as much as if you carried the so called Alzheimer's gene, apo E four. In our next story, we look at the role of meat on Alzheimer's disease. What is behind the dramatic increase in dementia in Japan over recent decades? Maybe it's rising obesity rates or the increases in cholesterol saturated fat and iron from increases in animal products and meat. Overall calories just went up about 10% in Japan whereas animal fat and meat consumption rose 500%, about ten times the rise in sugary junk. Now, during this time spent rice consumption went down, but the thinking is that rather than white rice, somehow being protective, maybe they were just eating something worse instead. It's like when you find fish consumption is correlated with less disease. You wonder if it's because they're eating that rather than some worse meat. If you look across multiple countries, you see a similar pattern with the most important dietary link to Alzheimer's appearing to be meat consumption with eggs and high fat dairy also may be contributing. There appears to be a really tight correlation between Alzheimer's and per CAPiTA meat supply. And then studies within countries uncover similar findings with Alzheimer's and cognitive decline associated with meaty, sweety, fatty diets, whereas most plant foods were associated with risk reduction. This could be for a variety of reasons, animal products tend to have more copper mercury, lead, and cadmium, no folate, but contain saturated fat and cholesterol, and pro inflammatory advanced glycation end products. So many mechanisms that dietary modification may be our best bet for reducing risk of Alzheimer's disease. But how do we know it's cause and effect? The evidence that meat consumption is causally linked to Alzheimer's disease. Well, there's the strength of the association, the consistency across different types of studies. The fact that the dietary change is preceded the risk of dementia, the dose response, more meat linked to more risk. A bunch of plausible mechanisms. We know meat is risk factor for other chronic diseases. But there's never been a randomized controlled trial to put it to the test. When you read reviews of the damaging effects of high fat diets to the brain and cognition, number of factors are proposed to account for the high fat diet induced damage to the brain, oxidative stress insulin resistance inflammation and changes to blood vessels of the integrity of the blood brain barrier, but these are based mostly on studies of rodents. Yes, high fat diets can cause energy dysfunction in the brain based on fancy MRI techniques, with CT scans, you can follow this intracranial artery stenosis, this brain artery clogging over time, and follow the progression from mild cognitive impairment to Alzheimer's disease. Those who only had low grade stenosis are pretty stable over time in terms of their cognitive function, and ability to dress themselves in other activities of daily living. Whereas those with more clogging started slipping over the years, and those who started out with the most brain atherosclerosis rapidly went downhill, and twice as likely to progress to full blown Alzheimer's. Chronic consumption of standard western diets enriched in saturated fat and cholesterol may compromise are cerebral vascular integrity, compromised the blood vessels in our brain. So, of course, drugs are recommended. Pharmacological modulation of diet induced dysfunction, but why not just try to eat healthier in the first place?
AP News Radio
Medicare proposes restricting coverage of Alzheimer's drug
"Medicare Medicare is is putting putting limits limits on on coverage coverage of of a a pricey pricey and and controversial controversial new new drugs drugs for for Alzheimer's Alzheimer's disease disease drugmaker drugmaker Biogen Biogen says says it it disagrees disagrees with with Medicare's Medicare's decision decision to to limit limit coverage coverage of of their their new new Alzheimer's Alzheimer's drug drug ads ads you you held held the the treatment treatment is is delivered delivered by by IV IV in in cost cost twenty twenty eight eight thousand thousand dollars dollars a a year year the the centers centers for for Medicare Medicare and and Medicaid Medicaid services services says says that that for for Medicare Medicare to to pay pay patients patients taking taking the the drug drug will will have have to to be be part part of of clinical clinical trials trials to to assess assess the the drug drug safety safety and and effectiveness effectiveness in in slowing slowing the the progression progression of of early early stage stage dementia dementia the the medicine medicine has has not not been been shown shown to to reverse reverse or or significantly significantly slow slow Alzheimer's Alzheimer's but but the the FDA FDA approved approved it it against against the the recommendation recommendation of of outside outside advisers advisers saying saying that that its its ability ability to to reduce reduce costs costs of of plaque plaque in in the the brain brain is is likely likely to to work work there there will will be be a a public public comment comment period period and and further further evaluation evaluation before before the the decision decision becomes becomes final final in in mid mid April April Jennifer Jennifer king king Washington Washington Medicare Medicare is is putting putting limits limits on on coverage coverage of of a a pricey pricey and and controversial controversial new new drugs drugs for for Alzheimer's Alzheimer's disease disease drugmaker drugmaker
Fading Memories: Alzheimer's Caregiver Support
How to Recognise the Signs of Alzheimer's Disease
"We start with the, the warning signs of Alzheimer's. What's what's an actual warning sign? And what is actual related to normal aging? Which is actually having this conversation with our friends. Last night, really good friend has a tendency to do about 15 things at once, and can't seem to remember what she's doing. And I think I know for because it hasn't changed in fifteen years that that's just life is and not paying attention. So we're can we start there? Sure. So, you know, there's certainly as we get older and our brain shrinks, we start off some capacity, some cognitive capacity that is, you know, considered the normal aging process, but you know, in today's day and age, we really give very little leeway for that just to remind people, you know, our grandparents, you know, in the 1960s, 70s 80s as they got older, they became senile and that word is really fallen out of favor. So we don't really talk so much about senility as the diagnosis or excuse for having, you know, poor memory or or function. It's not to say that the dog. Not any change that occurs with aging but we really won't get towards. Is there more of a problem. And when we start thinking about dementia, which is the big umbrella term that we think about and, and Alzheimer's disease being the most, common one, there has to be memory loss. So that's a that's, that's a symptom and assigned really, that has to be there. And then there has to be some sort of dysfunction in other what we call spheres of cognition, and probably the easiest one that to talk about is something called executive functioning. So when you go see a neurologist Thursday, we are you know, you're going to be asked questions about who does the who does the bills at home? What are what are the what are the what's the capacity to pay the bills and somebody who may be paid bills forever in their adult life? And all of a sudden now a spouse or a child has to double-check. There's late payments. There's overdrawn on a checking accounts things like that is the ability to sort of have this high-level executive wage. Ocean is a is really a sign that there's something perhaps going on, much more than just. Oh, I can't remember that
AP News Radio
Tony Bennett Cancels Fall and Winter Touring Dates in 2021
"Legendary singer Tony Bennett is retiring from live performances if you were hoping to see Tony Bennett perform in person your opportunity may have passed the ninety five year old Grammy winner had canceled his upcoming twenty twenty one tour because of the cobit nineteen pandemic and now his son tells reporters Bennett won't be going on the road again Bennett had concerts planned in the northeast Arizona Oklahoma and Canada despite being diagnosed with Alzheimer's disease but those dates won't be rescheduled earlier this month Bennett had teamed up with lady Gaga for two nights at new York's Radio City Music Hall the shows were filmed for broadcast at a later date and these may be the final live performances of his seventy year career I'm Jackie Quinn
Broken Brain with Dhru Purohit
Evidence That Early Alzheimer’s Can Be Reversed With Dr. Dale Bredesen
"I want to start with a big picture question that a lot of people who are listening to this podcast watchings view on youtube one. Oh which is is it truly possible to recover from alzheimer's it's a loaded question and some people might even say it's a blasphemous question right. But you're the man to ask. I would agree with you. It's blasphemous but absolutely we've seen it again and again and again As proof for example we just published a our trial proof of concept trial In that trial eighty four percent of the people actually improve their scores so we have unquestionable objective evidence of improvement. And when you say you publish your trial right for those folks that are just new to you right and are not familiar with your protocol program that you've designed. Let's give a little bit of context around this. What was that trial trying to look bad. And what answers came from it. Yeah great point so way back in two thousand eleven we were looking at root causes as as you well know root cause medicine is critical and so we were looking at root causes of cognitive decline in two thousand eleven. We proposed the first comprehensive trial for people with mci or alzheimer's. And let me. just digress. For one moment to say this concept of mci mild cognitive impairment has really hurt people and the field when you say that someone has mild cognitive impairment that is like saying they have mildly metastatic cancer. It is a late stage of the process. Typically they've had the underlying pathophysiology for fifteen or twenty years before they're getting a diagnosis of mci and then about each year. About ten percent of those people will convert to full on alzheimer's which is a which is the end stage of really. What is the alzheimer's pathophysiology and just pause there for a second. If you could rename that right come up with a different term just to show people the severity in the weight that comes with data. Is there any thoughts of what you would wanna call that absolutely so there are four stages you a symptomatic subject of cognitive impairment. Mild cognitive impairment and alzheimer's what they should be called is pre alzheimer's. That's the that's the A symptomatic period. Subjective is early stage. alzheimer's disease what we call. mild mild. Cognitive impairment is advanced stage alzheimer's disease. And what we currently call. Alzheimer's disease is final stage
Science Magazine Podcast
Approval of New Alzheimer's Drug Could See Surge in Blood Tests
"Last year about six million people in the us. We're living with alzheimer's disease and by twenty sixty that number could be as many as fourteen million people living with the disease. There's no cure and it's not easy to tell if someone has it from symptoms alone. The testing for alzheimer's is invasive and resource and pensive staff writer. Kelly servic is here to discuss. How testing the blood for alzheimer's might facilitate new treatments and new research. Hi kelly hi sarah alright. So this is kinda spurred on by the approval of a potential treatment for alzheimer's disease. I'm not going to say the name of the struggle. I'm going to leave that to you. It's very long but it's really put a spotlight on this issue of testing for the disease in the blood. Why is that first of all. Fda really surprised a lot of people by approving this drug called kanye mab marketed as as you home for alzheimer's and that that approval was special. Not just because there hasn't been an alzheimer's drug approved in more than a decade but also because this is the first approved drug that aims to actually interfere with the underlying disease process and slow the progression of disease and the reason that that is shaken. Things up is that essentially a lot of older people with memory problems. Who did not see care. Did not seek an alzheimer's diagnosis before. Might do so now that there is an available treatment. And what they would do to get screened would be what get speidel. Fluid take it out so diagnosing. Alzheimer's is really complicated. There other neurological conditions that can cause dementia and an older people a lot of other factors. That might contribute to their memory. Problems and as a result really confirming alzheimer's diagnosis requires waiting to get assessed by a specialist and be assured as you can be either getting a pet scan which is expensive. And there aren't a ton of pet scanners in this country or spinal tap so that your spinal fluid can be analyzed for certain
News, Traffic and Weather
Biogen Shares Down 7%
"Today. That's after United Health Group said it needed more time to determine its coverage policy for the biotech companies recently approved $56,000 Alzheimer's disease, drug addled film that's expected to raise costs for the U. S government's Medicare program. It's official. The Emerald
Dr. Jockers Functional Nutrition
Top Benefits of a Ketogenic Lifestyle
"Chronic sugar burning mode when their sugar burners they're producing a lot of metabolic waste that's damaging their cells and very little energy. it's energy inefficient. We want to create metabolic flexibility. Where we have the ability to not only use sugar. We need to but really to use fat or key tunes as an energy source. And there's nothing better for that than the ketogenic diet and lifestyle and so the top benefits number one reducing really. Stabilizing your blood sugar. So reducing it and then balancing it at a really good point and what does that do. That's going to give you better. Mental emotional stability one of the worst things we can do for. Our body has have blood sugar imbalances. We eat a meal blood. Sugar jumps way up then it crashes down. Our body produces the hormone called insulin. Insulin take sugar out of the bloodstream. Puts into the cells when it does that it also triggers inflammation and we have elevated insulin. It stores fat so we actually are unable to burn fat for fuel. We actually have storing fat so a ketogenic diet and lifestyle helps balance your blood. Sugar helps improve your mental emotional state and helps your body become more resilient to stress test. Really the second benefit is this resiliency to stress and mental emotional balance the third benefit as it reduces inflammation in your body so we burned sugar. We produce a ton of oxidative stress and free radicals and when that happens we allot of inflammation and that inflammation tears down major tissues barbati and ultimately over time leads the development of chronic disease whether it's chronic pain in our body whether it's organs that are malfunctioning. Wonder it's our brain losing our memory if it's brain fog early on or depression. These are inflammatory. Conditions long-term it ends up being something like dementia alzheimer's disease in our brains. So we gotta make sure reducing implementation ketogenic diet and lifestyle really really good. At doing exactly that k- the fourth big thing is
AP News Radio
FDA Trims Use of Contentious Alzheimer's Drug Amid Backlash
"Federal health regulators are putting new limits on the recommended use of a controversial new Alzheimer's drugs a month after proving add you helm for patients with Alzheimer's disease the food and drug administration approved new labeling that the drug is appropriate for patients with mild symptoms or early stage Alzheimer's noting it hasn't been studied in patients with more advanced disease the change was to help eliminate confusion among doctors about who should be taking the medicine add to home hasn't been shown to reverse or significantly slow Alzheimer's disease but the FDA says its ability to reduce clumps of plaque in the brain is likely to slow dementia many experts are skeptical and three of FDA's outside advisers resigned over the drugs recent approval Jackie Quinn Washington
The Readout Loud
FDA Grants Accelerated Approval for Alzheimer's Drug
"So what would this pike. Sp if it didn't start with an update on adam damian's favorite drug guys. There's more news on that front this week. Catch us up right so the hot off. The presses aspect came out just thursday morning which is that. The fda restricted the label for which you helm is approved basically advising doctors to prescribe the drug solely to patients who mostly matched the population in which it was studied in face retrials this. I mean the implications of this we can. We can kind of talk about but you know one of the shocking things really probably to me. The most shocking thing on the day that agile home was approved was the breadth of the fda's label. The drug was indicated for anyone with alzheimer's disease at any stage of the disease regardless of what their sort of brain biology was. And as we know this drug is meant to clear out plaques from the brain that purported to contribute to the advanced alzheimer's and so that label was was fairly galling honestly and so the fda mostly walking it back to what people had expected for those people who even expected approval. was interesting. I feel like it might have fewer implications for the way the drug is actually used. Because i think that physicians indefinitely biogen were thinking that that it would only go to to this narrower group of patients but maybe just has more more implications for our fixation on the fda and what is going on there.
Broken Brain with Dhru Purohit
How Insulin Resistance Destroys Your Brain and Promotes Alzheimers
"Dr ben beckmann. Welcome back to the podcast. It's an honor to have you here again brother. Oh man i'm delighted. We had such a good time the first time that we thought why not do it again. I'm glad to be here. Why not do it again and we have a whole new topic. There's gonna be some overlaps with the other interview that we did and for anybody who didn't listen. Check out the show notes. We'll talk about some of those topics again here. But today's conversation diving into the topics of alzheimer's dementia cognitive decline even brain fog and lack of focus in how to understand how the brain works and what fuel sources run and what fuel sources potentially harm it. So i want to just jump right in. You know we've spent. I don't know the exact number. It's in the billions of dollars of money spent on alzheimer's and cognitive decline based drugs and for the most part even very centrist in western medicine. tell you we've gotten very little from it and on top of that. There's millions of people around the globe that are still suffering from these chronic diseases and the ones that aren't suffering. They're well on their way to getting it and alzheimer's and dementia are one of the most of diseases even scarier on a lot of national surveys. Then even cancer. So i'd love to start off big picture with the billions that we spent with the hundreds of thousands of people that are interested in this topic paying attention to it thousands of researchers. What are we missing when it comes to this conversation. Yeah to there's no question we need to shift the paradigm to use a worn out cliche. Perhaps but we. We've been classically looking at alzheimer's disease the same way now for decades which is that. It's really a disease of two problems. In the brain one is the accumulation of these amyloid beta peptides or these plaques. They're called in the other one. Is these Neurofibrillary tangles that the neurons which ought to be You have a clear. Direct structure are getting messy. The problem with those To identifiers well is one. they're hard to identify. Those are only things you can identify. Essentially post
CRISPR Cuts
"alzheimer disease" Discussed on CRISPR Cuts
"The associated quality control data for those lines and then put in a request. Hopefully with a very very easy to use click. Mta is our goal so that investigators can really efficiently request. These lines in the mishandled by jets has a long history of distributing reagents community for example the mice very efficiently. Very high quality very quickly. And so we're partnering with them for this. They're so good. At distribution addition to genome engineering skills. That is great. Finglas gaustad not serving networks. Everyone would definitely be looking forward to that. Mike you had mentioned recent paper. And i've seen that just went indie game out. I think it came out in a few days after that. You had fourteen Lines looking at atkinson's right. So is that also going to be. I also looking to make that available.
AP News Radio
FDA Approves Much-Debated Alzheimer’s Drug Panned by Experts
"The food and drug administration approved the first new drug for Alzheimer's disease in nearly twenty years but there were doubts the drug is from Biogen magic can amount which is now could be marketed as and you held the FDA approved the drug saying it was based on results that seems reasonably likely to benefit Alzheimer's patients Dr Maria Correo is chief science officer with the Alzheimer's association this therapy slows the progression of the disease because it addresses the underlying biology one of the hallmarks of Alzheimer's which is amyloid plaques therapy usually manages symptoms of Alzheimer's like insomnia or anxiety FDA advisor Dr Caleb Alexander said no to the drug's approval he said the agency has regulatory standards based on evidence but in this case he thinks the product get a pass at Donahue Washington
AP 24 Hour News
First New Drug for Alzheimer's in 20 Years Approved by FDA
"And Drug Administration approved the first drug they say may help slow Alzheimer's disease. It's a surprise decision. The FDA is independent advisor said the treatment hadn't been shown to help treat Alzheimer's. The drug from Biogen is the first new Alzheimer's treatment in nearly 20 years, The
Bloomberg Businessweek
Alzheimer’s Drug From Biogen Wins US Approval
"Service prices as we're seeing activity picking up Biogen has received approval for its controversial Alzheimer's disease, their appeal landmark decision that stands to dramatically change treatment for the debilitating brain condition. Bijan shares up now by 40.2%. Japan's A Sigh is working with Bijan on the Alzheimer's drug. It's a TRS are also surgeon today.
The Peter Attia Drive
"alzheimer disease" Discussed on The Peter Attia Drive
"Specializes in alzheimer's disease clinical research along with the diagnosis and treatment of patients with a d. And other memory disorders. She's an active member in the memory disorder community and i actually met her through our shared interest in a nonprofit that you may have heard of hilarity for charity in this episode. We talked about a number of things. Obviously her background and what drew her into a field. That many people don't necessarily think of geriatric psychiatry as a field pertaining to alzheimer's disease. We talk a lot about the clinical diagnosis of alzheimer's disease which actually is still somewhat elusive. And while it's easier to make the diagnosis today than say twenty years ago. It's still far from perfect diagnosis. And a number of other things need to be ruled out. We get into a pretty good discussion around the pharmacotherapy pipeline. There are at this time over a hundred drugs in the regulatory pipeline for testing. And we get into a discussion of where they are in that phase and what they're targeting. We discuss specifically a drug called out of canada mob. Which is a monoclonal antibody directed at amyloid beta. And at the time of this podcast. It is very tenuously awaiting. Fda approval a decision that should be rendered on june seventh. This is a very important moment for the research community because if approved it would be the first drug approved both as a monoclonal antibody and secondly as a drug that is a disease modifying drug as opposed to a symptom based drug which is currently. All we have in the quiver. We conclude the discussion by talking about what it means to age in a healthy way. And i think this is the part that probably has the broadest application. Because even if you don't develop alzheimer's disease you will age. That is inevitable and the insights that amanda provides here are going to be valuable for everyone. I certainly feel that way myself so without further delay. Please enjoy my conversation with dr. Amanda thank you so much for making time to chat with me today from the first time i heard you speak. I knew i wanted to have you on the podcast. You probably don't even remember when that was do you..
The Readout Loud
FDA Approval of New Alzheimer’s Drug May Boost Prospects
"Today. I think really take this week on reading. The the fda tea leaves of drug approved ability. We'll thank you. Say but yeah. I think you know we are basically on the eve of what is expected to be. This momentous decision by the fda on canyon have the controversial alzheimer's disease treatment from biogen and because there isn't really much to do in terms of trying to predict that decision. There isn't much information to pick apart. I think people you know resort to to what we all would which is maybe not quite tinfoil hat but we look at whatever evidence there is and try to construct a take and so for months. I think there's been this. Focus especially in the investor community on parsing each individual. Fda decision for clues as to some sort of like meta take on how the agency is thinking about new drugs. Yeah i mean you know. There's this idea right like you know is the fda being more conservative would drag approvals. Is it being more flexible. Which approvals right and it has come to feel a little bit absurd so if there's a run of as there were a few months ago surprising decisions whether it be Rejections or you know. Advisory committee hearings called where they weren't previously expected then. Suddenly the vibe is oh well. They're really cracking down. And then recently we had to Drug approvals in consecutive weeks. That came through. Let's say favorably to the drug companies and sort of undramatically so then the vibes us the fda in fact. They've kind of taken their foot off the brake when it comes to this and i think you know everybody probably knows this. But the is comprised of thousands of people And even the drug review arm is separated into individual fiefdoms focused on you know different aspects of biology and science and types of drugs etc and each one has its own internal politics. Each one has its own personnel changes in its own kind of regulatory philosophy. It's different between cancer than it is from neuroscience for example and so i guess it's one of those things where reading these tea leaves has kind of maybe run out of clues to offer us and maybe we should all just kind of respected. It's a giant organization and we are on the outside of it.
WISH TV's News 8 Daybreak
Jack Hanna, Beloved Animal Expert, Stepping Away Because of Dementia
"Life. Jack Hanna has Alzheimer's disease. In a letter posted by the Columbus Sue, the Hana family says his diagnosis was has progressed quickly over the last few months. His family made the announcement yesterday. Hannah is well known for his live animal demonstrations on late night talk shows. He retired last year. The animal lovers daughters. Say he still has a great sense of humor and still wears his khakis at home. Jack Hanna's into the Wild airs Saturdays at 11 in the morning on Wish TV. It's 5 39 cicadas air set